Kestra Medical (KMTS) Q4 2026 earnings review
Hyper-Growth Continues, But So Does the Cash Burn
Kestra Medical concluded a blowout FY26 with Q4 revenue surging 66% to $28.6M, driven by massive prescription growth (+63%) for its ASSURE system. The company is successfully executing its playbook: gaining market share from the incumbent while expanding gross margins (up to 54.8%) by securing more in-network payer contracts. However, the cost of this aggressive commercial expansion is steep. Adjusted operating expenses spiked to $44.7M in Q4, widening the Adjusted EBITDA loss to $26.7M. While management guided FY27 revenue to $137M (a 44% increase), this implies a deceleration from the Q4 exit velocity. Kestra is firmly in a land-grab phase, prioritizing top-line growth and market penetration over near-term profitability.
🐂 Bull Case
Q4 revenue growth accelerated to 66% YoY, driven by a 63% increase in ASSURE prescriptions (6,357 in Q4). Kestra is aggressively and successfully taking share in the underpenetrated Wearable Cardioverter Defibrillator (WCD) market.
Gross margin reached 54.8% in Q4 (up from 44.3% YoY). This marks continuous sequential margin expansion, proving the unit economics of their rental model as in-network payer coverage improves.
🐻 Bear Case
Despite record gross margins, GAAP operating expenses hit $55.0M in Q4. Excluding stock-based comp, adjusted OPEX was $44.7M, a 50% YoY increase that drove the Adjusted EBITDA loss deeper into the red.
Initial FY27 guidance of $137M implies 44% YoY growth. While objectively strong, it represents a visible deceleration from FY26's 59% growth and Q4's 66% pace.
⚖️ Verdict: 🟢
Bullish. The widening EBITDA loss is a feature, not a bug, of Kestra's current strategy. The company is well-capitalized ($262M in liquidity) to fund this commercial land-grab. Sustained 60%+ prescription growth and expanding gross margins prove the product and go-to-market strategy are working.
Key Themes
In-Network Mix Unlocking Gross Margin Leverage
Kestra's most impressive financial feat is its relentless gross margin expansion. Q4 gross margin expanded to 54.8%, up from 44.3% a year ago. This accelerating trend is driven by volume leverage and a deliberate strategy to shift patients to in-network contracts, which drastically improves revenue cycle management and conversion rates. Management previously outlined a path to 70%+ gross margins, and current pacing supports this trajectory.
Market Share Gains and TAM Penetration
With 6,357 ASSURE prescriptions written in Q4 (+63% YoY) and over 20,000 for the full year, Kestra is executing a dual-pronged strategy: cannibalizing the incumbent (ZOLL) and expanding the total WCD market. Historically, management estimated only ~14% of the eligible U.S. WCD market is penetrated. The compelling primary results from Kestra's FDA post-approval study (ACE PAS) are serving as a critical wedge to convince prescribers of the high sudden cardiac arrest risk in the first 90 days post-hospitalization.
Aggressive Commercial Expansion
The primary engine behind Kestra's 66% Q4 revenue growth is the rapid scaling of its sales organization. The company entered FY26 with roughly 80 territories and has been aggressively hiring to double that footprint. This expansion targets high-volume geographies where Kestra has already secured strong payer coverage, allowing new reps to ramp productivity quickly.
Widening Losses Contradict Margin Success
While the gross margin narrative is flawless, the bottom-line reality is sobering. Adjusted operating expenses jumped 50% YoY to $44.7M in Q4. Consequently, despite adding $8M in incremental gross profit YoY during the quarter, Kestra's Adjusted EBITDA loss widened from $20.3M to $26.7M. The massive investment in sales reps and commercial infrastructure is completely absorbing the gross margin gains, delaying any near-term path to cash flow breakeven.
Entrenched Incumbent Risk
Kestra is facing off against a massive, well-capitalized incumbent. While Kestra has dismissed competitor upgrades in previous quarters as a 'slow launch,' the sheer size of the competitor means any shift in their pricing strategy, clinical positioning, or aggressive counter-detailing could pressure Kestra's growth trajectory and require even heavier sales and marketing investments to maintain momentum.
Macro Industry Environment: Clinical Guidelines
To double or triple the WCD market, formal updates to the 2017 clinical guidelines will eventually be required. Management previously noted that the arrhythmia committee meets on an ad hoc basis. Kestra is heavily leaning on its 21,000-patient ACE PAS data to force this conversation, but the timeline remains entirely out of the company's control.
Other KPIs
Accelerating. Up 63% YoY. This unit volume is the bedrock of Kestra's financial model. Full-year prescriptions hit 20,720 (+57% YoY), indicating that demand generation strengthened as the year progressed.
Maintained robust liquidity following their December 2025 equity raise. While net cash used in operating activities for FY26 was $81.7M, the current balance sheet provides ample runway to fund the ongoing commercial expansion without near-term dilution risk.
Worsened from a loss of $113.8M in FY25. This includes $33.6M in share-based compensation expense (up from $24.3M in FY25) and heavy R&D and SG&A investments. Operating leverage has not yet reached the bottom line.
Guidance
Decelerating. This target represents 44% YoY growth over FY26's $95.1M. While 44% is an exceptional growth rate for medtech, it is a sequential deceleration from the 66% growth delivered in Q4 FY26 and the 59% growth achieved for the full FY26 year. Management is likely leaving room for beat-and-raise cycles, but the law of large numbers is beginning to weigh on percentage growth.
Key Questions
Pacing of Sales Expansion
With adjusted operating expenses jumping over 50% in Q4, how many sales territories are embedded in the FY27 $137M revenue guidance? Are you expecting a plateau in territory additions, or will hyper-expansion continue?
Biobeat Integration Timeline
Regarding the strategic collaboration with Biobeat Technologies, when do you expect cuffless blood pressure monitoring to be commercially integrated into the ASSURE system, and will this command a premium reimbursement rate?
Path to Profitability
Given the widening Adjusted EBITDA loss in Q4 despite record gross margins, at what revenue run-rate do you anticipate generating positive Adjusted EBITDA?